David Yan

Responsible for the company's Portfolio strategy, licensing in & out, M&A and alliance management etc.

• Develop inorganic growth strategy, work closely with Business Unit and Function leaders to source, structure, and implement corporate development deals. o Have concluded average 1~2 deals annually, to meet the company portfolio selling approach • New Product Introduction & Portfolio Management o Develop China portfolio strategy and business cases in core Therapeutic Areas; Once they are approved and implemented, closely monitoring and ensuring new products’ launch on time. • Corporate L&A Support o Help conducting systematic screening --> Full commercial assessment of potential candidates  due diligence --> Negotiation and contracting --> Till signature of the agreements.

Leading role in developing and implementing brand strategy to maximize CNS brands' performance in China atypical antipsychotic market (5 direct reporters) Set and control, management of all marketing activities, and coaching and leadership of cross functional brand team Leading cross-functional project teams effectively engaged with global licensing team and also managed AZ pipelines covering Oncology/ CNS /infection therapeutic areas. One achievement was, as a major contributor, to in-license Cubicin (an IV antibiotic) from an US biotech -Cubist Working with BCG/McKinney, successfully delivered several strategic projects for the company, incl.10-years disease strategy and licensing screening project etc.

reported to BU director Responsible for a group of anti-infective products, sales around RMB 200M business annually Major achievement- Successful Product Life Cycle Management Given the most competitive and challenging situation in infection, three CSFs were identified as our Effort priorities, which are Product Assess- Ensure bidding and tendering in key markets and maintenance on hospital listing. Brand Loyalty- Maintain High prescribers' brand loyalty by keeping SOV in target segments, which was based on an accurate and continually updated customer database. KOLs' endorsement- by continually sponsoring local surveillance study to generate favorite data supporting products' claims By adopting the "focus" strategy, i had been successfully achieved the portfolio sales above RMB200M, meanwhile, achieving one of major mature brands, 'Fortum', 8% annual growth during 2004~2005.

Restructure the MKT and strengthen company image and key brands in related therapeutical area. Product portfolio management and strategic planning for 5 years' business development

GI & Antidepressant Successfully launched an antidepressant- Luvox in China, resulting RMB 20M sales in launch year. Established China IBS research club, built strong relationship with KOLs in the GI field.

Zhejiang, Fujian and Jiangxi Aggressively expanded antibiotic products to Tier 2 cities, resulting in 32% increase of regional sales and sales target was constantly being exceeded by 20-30% annually.

Surgeon, Be regarded as a professional and responsible person by colleagues and patients